References
- Costa-Motta FM, Acosta AX, Abe-Sandes K, Bender F, Schwartz IV, Giugliani R, et al. Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brazil. Mol Genet Metab 2011;104:603-7. https://doi.org/10.1016/j.ymgme.2011.09.017
- Poupetova H, Ledvinova J, Berna L, Dvorakova L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010;33:387-96. https://doi.org/10.1007/s10545-010-9093-7
- Lin WD, Lin SP, Wang CH, Hwu WL, Chuang CK, Lin SJ, et al. Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients. Clin Chim Acta 2008;394:89-93. https://doi.org/10.1016/j.cca.2008.04.014
- Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010;5:5. https://doi.org/10.1186/1750-1172-5-5
- Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149A:960-4. https://doi.org/10.1002/ajmg.a.32781
- Schaap T, Bach G. Incidence of mucopolysaccharidoses in Israel: is Hunter disease a "Jewish disease"? Hum Genet 1980;56:221-3. https://doi.org/10.1007/BF00295699
- Wicker G, Prill V, Brooks D, Gibson G, Hopwood J, von Figura K, et al. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B. J Biol Chem 1991;266:21386-91.
- Isbrandt D, Arlt G, Brooks DA, Hopwood JJ, von Figura K, Peters C. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet 1994;54:454-63.
- Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9. https://doi.org/10.1016/j.jpeds.2005.12.014
- Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010;33:51-60.
- Gajdosik RL, Bohannon RW. Clinical measurement of range of motion. Review of goniometry emphasizing reliability and validity. Phys Ther 1987;67:1867-72. https://doi.org/10.1093/ptj/67.12.1867
- Bolton JW, Weiman DS, Haynes JL, Hornung CA, Olsen GN, Almond CH. Stair climbing as an indicator of pulmonary function. Chest 1987;92:783-8. https://doi.org/10.1378/chest.92.5.783
- Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001;119:256-70. https://doi.org/10.1378/chest.119.1.256
- Sohn YB, Park SW, Kim SH, Cho SY, Ji ST, Kwon EK, et al. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation. Am J Med Genet A 2012;158A:1158-63. https://doi.org/10.1002/ajmg.a.35263
- Kampmann C, Lampe C, Whybra-Trumpler C, Wiethoff CM, Mengel E, Arash L, et al. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis 2014;37:269-76. https://doi.org/10.1007/s10545-013-9649-4
- Varssano D, Cohen EJ, Nelson LB, Eagle RC, Jr. Corneal transplantation in Maroteaux-Lamy syndrome. Arch Ophthalmol 1997;115:428-9. https://doi.org/10.1001/archopht.1997.01100150430024
- Furujo M, Kubo T, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 2011;104:597-602. https://doi.org/10.1016/j.ymgme.2011.08.029
- Kantaputra PN, Kayserili H, Guven Y, Kantaputra W, Balci MC, Tanpaiboon P, et al. Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet A 2014;164A:1443-53.
- Okamura K, Munkhbat B, Batchimeg B, Tamiya G, Hozumi Y, Suzuki T. Case of a Mongolian child with extensive Mongolian spots in mucopolysaccharidosis type VI: identification of a novel mutation in the arylsulfatase B gene. J Dermatol 2013;40:758-9. https://doi.org/10.1111/1346-8138.12237
- Giugliani R, Lampe C, Guffon N, Ketteridge D, Leao-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A 2014.
- Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 2013;36:373-84. https://doi.org/10.1007/s10545-011-9410-9
- Lin HY, Chen MR, Chuang CK, Chen CP, Lin DS, Chien YH, et al. Enzyme replacement therapy for mucopolysaccharidosis VI--experience in Taiwan. J Inherit Metab Dis 2010;33 Suppl 3:S421-7.